Functional Diagnostics in Maryland

Segami Corporation is a medical software company specializing in vendor-neutral nuclear medicine imaging solutions. The company's flagship product, Oasis V3, is a nuclear medicine reading and processing platform designed to streamline image interpretation and workflow efficiency for radiologists and nuclear medicine technologists. Oasis V3 integrates seamlessly with all major nuclear medicine imaging modalities, including SPECT/CT, PET/CT, and PET/CT/MR systems from multiple manufacturers, eliminating vendor lock-in and enabling flexible, multi-vendor department operations. The software provides comprehensive image processing, analysis, and review capabilities across oncology, cardiology, neurology, and general nuclear medicine applications. Key features include efficient image manipulation, clinical data extraction, and tools supporting rapid, accurate diagnosis and treatment planning. The platform is designed to enhance departmental capabilities and patient care outcomes through streamlined workflows and precise diagnostic support. Segami serves leading healthcare institutions globally and maintains offices in the United States (Columbia, Maryland) and Canada (Laval, Quebec).

Aromha Inc develops and commercializes the Aromha Brain Health Test, a non-invasive, at-home olfactory screening tool designed for early detection of cognitive decline and neurodegenerative diseases, particularly Alzheimer's Disease and related dementias. The test was developed by Dr. Mark Albers, an Assistant Professor of Neurology at Harvard Medical School and Massachusetts General Hospital, and leverages research showing that olfactory dysfunction correlates with Alzheimer's Disease pathology years before symptom onset. The assessment consists of a simple smell test coupled with a user-friendly web-based application that delivers personalized insights and recommendations. The company targets individuals concerned about memory loss, cognitive decline, or family history of dementia, positioning early detection as enabling informed clinical decision-making, lifestyle interventions (exercise, sleep, diet), participation in early-stage clinical trials, and proactive life planning. The test is marketed directly to consumers and has received significant media coverage from news outlets including NBC Boston, WCVB, and NewsNation. The company is based in the Washington, DC metropolitan area and focuses on democratizing access to cognitive health screening outside traditional clinical settings.

PediaMetrix is a healthcare technology company specializing in AI and computer vision solutions for pediatric care. The company's flagship product, SoftSpot™, is the first and only FDA-cleared mobile application for point-of-care measurements of infant head deformity conditions, including positional plagiocephaly and other cranial abnormalities. SoftSpot enables both pediatric providers and parents to perform quantitative, repeatable head shape assessments using smartphone-based computer vision technology, supporting early detection and monitoring in clinical and home environments. The platform is designed for telemedicine and in-office use, with results interpreted by qualified healthcare professionals. PediaMetrix also offers Tummy Time Tools to support infant developmental activities. The company's mission is to make advanced measurement technology accessible to improve patient outcomes and reduce costs in pediatric healthcare delivery while maintaining robust data security through encryption systems.

Tetracore, Inc is a diagnostics innovator specializing in the development and manufacture of reagents, assays, and portable instruments for the detection of infectious diseases and bioterrorism threat agents. Founded over 20 years ago and headquartered in Rockville, MD, the company serves domestic preparedness, forensic biology, human health, and veterinary sectors. Primary product lines include the T-COR 8 Real-Time PCR Thermocycler, a portable system for rapid on-site detection of biothreat, veterinary, and environmental samples; BioThreat Alert Reader VII, a portable lateral flow assay (LFA) reader; BioThreat Alert Rapid Test Strips for immunological and molecular detection of biological threat agents; real-time PCR kits and reagents for infectious disease and animal disease detection; and FlexImmArray multiplex assays for arbovirus and pathogen detection on Luminex and Bio-Plex platforms. The company also produces EZ-SARS-CoV-2 RT-PCR testing kits and VetAlert real-time PCR assays for animal health applications, including African Swine Fever monitoring. Tetracore holds ISO 9001, ISO 13485, and ISO/IEC 17025 accreditation certifications, demonstrating quality management and laboratory competence. The company's products are designed for rapid deployment in field and laboratory settings, emphasizing actionable results and ease of use for emergency response and disease surveillance.

Xcision Medical Systems develops the GammaPod, the first and only FDA-cleared stereotactic radiotherapy system specifically designed for early-stage breast cancer treatment. The company focuses exclusively on advancing breast cancer care through innovative radiation oncology technology. The GammaPod platform enables significantly shortened treatment courses (5 days or fewer) compared to conventional external beam radiation therapy (4–6 weeks), delivering non-invasive, non-surgical treatment with rapid recovery. The system uses advanced imaging and radiation delivery to provide patient-friendly, protective care for eligible early-stage breast cancer patients. Xcision is headquartered in Columbia, Maryland, and actively participates in major oncology conferences (ESTRO, Arab Health) and industry initiatives to modernize radiation oncology reimbursement. The company holds FDA clearance for the GammaPod and is engaged in clinical and commercial partnerships to expand access to this specialized breast cancer treatment modality.

3CPM Company, Inc. is a US-based medical device manufacturer specializing in electrogastrography (EGG) diagnostic systems for gastrointestinal motility disorders. The company's proprietary technology combines miniaturized hardware with AI-driven software for non-invasive characterization of gastroparesis, functional dyspepsia, and related GI conditions. The EGG platform features a simple 45-minute test protocol with automated signal acquisition and evidence-based diagnostic interpretation. 3CPM's patented technology enables disease subtyping to optimize personalized treatment selection and identify potentially curable subsets of patients (25% of gastroparesis and dyspepsia cases). The system provides objective diagnosis of dyspepsia, gastroparesis, reflux, motility disorders, pyloric dysfunction, and associated symptoms (nausea, vomiting, bloating, abdominal distension, and pain). Built on 30 years of AI development, device engineering, and medical simulation integration, the platform is FDA-approved as the only approved device for non-invasive electrogastrographic diagnosis. 3CPM markets to gastroenterology practices, hospitals, and ambulatory surgical centers, emphasizing improved patient outcomes, increased satisfaction, and positive cash flow for healthcare facilities.

Pearl Diagnostics is a Johns Hopkins University spin-off specializing in in vitro diagnostic assays for the detection of lung infections. The company's proprietary technology identifies circulating microbial extracellular vesicles (EVs) as biomarkers for early, non-invasive diagnosis of respiratory pathogens. Their lead product, MycoMEIA® Aspergillus Assay, received FDA 510(k) clearance in August 2025 and detects Aspergillus antigen in urine samples. The company is developing additional assays targeting common respiratory pathogens, including Pseudomonas aeruginosa, with support from the Cystic Fibrosis Foundation. Pearl Diagnostics serves infectious disease clinicians, pulmonologists, and hospital laboratories seeking non-invasive diagnostic tools for fungal and bacterial lung infections. The company provides technical support and educational resources to healthcare institutions.

Longhorn Vaccines and Diagnostics LLC is a veteran and family-owned biotech company with over 35 years of experience in human and animal public health. The company develops diagnostic tools, vaccines, and monoclonal antibodies targeting infectious diseases, antimicrobial resistance, and inflammatory conditions. Core products include PrimeStore® MTM, an FDA-cleared Class II molecular transport media (predicate device) for pathogen inactivation and RNA/DNA preservation in clinical samples; Salorn STM, a virucidal sample collection device for antigen testing; PrimeScreen MTB™, an oral screening kit for tuberculosis detection; PrimeSeqMDR, optimized PCR primers and reagents for MTB resistance gene amplification; and PrimeXtract™, a nucleic acid extraction system. In vaccines and therapeutics, Longhorn develops composite peptide vaccines addressing bacterial sepsis and antimicrobial-resistant infections, and monoclonal antibodies (e.g., LHNVD-501, LHNVD-303) targeting multi-drug resistant bacterial pathogens. The company is recognized by FDA, WHO, USDA, UK Health Department, and NHS. Manufacturing and supply partnerships are based in the United States, ensuring quality and accessibility. Longhorn's products address sample collection, transport, nucleic acid extraction, molecular testing, and therapeutic prevention of infectious and inflammatory disease.

Radiopharmaceutical Imaging and Dosimetry (Rapid), LLC is a Baltimore-based biotechnology research company founded by Johns Hopkins University experts (Drs. George Sgouros, Eric Frey, and Michael Ghaly). Rapid specializes in quantitative imaging, dosimetry analysis, and precision medicine support for radiopharmaceutical therapies, particularly in oncology. The company provides comprehensive consulting and centralized solutions covering the full workflow from image acquisition protocol development through regulatory support and dosimetry reporting. Services include agent-specific imaging protocol design, centralized vendor-independent SPECT/CT quantitative reconstruction with advanced scatter and crosstalk compensation, and expert dosimetry analysis to optimize patient outcomes and reduce normal organ toxicity. Rapid also develops software solutions, including 3D-RD-S, a SaaS platform for radiopharmaceutical dosimetry calculations and radiobiological response modeling. The company combines 45+ years of NIH-funded research and development experience to standardize and simplify dosimetry for routine precision dosing of radiopharmaceutical therapies.